Overview

Interferons (IFNs) are a family of signaling proteins produced and secreted by host cells in response to pathogens or abnormal cells. They are members of the larger class of cytokines and are glycoproteins that act as key mediators of the innate immune response. The name "interferon" reflects their original characterization as factors that "interfere" with viral replication inside infected cells. In addition to direct antiviral effects, interferons influence antigen presentation, immune cell activation, and cell proliferation.

Types and basic characteristics

Mammalian interferons are grouped into three major types based on the receptors they use and their genetic relationships: type I (including multiple IFN-alpha subtypes, IFN-beta and related forms), type II (the single IFN-gamma) and type III (IFN-lambda family). Each type binds distinct cell-surface receptors and initiates intracellular signaling. Human genomes encode several IFN genes; different tissues and cell types express distinct interferons in response to stimuli.

Mechanism of action

When interferons bind their receptors on target cells they activate intracellular kinases and transcription factors, most notably the JAK–STAT pathway. This signaling cascade induces expression of interferon-stimulated genes (ISGs) that establish an "antiviral state": proteins encoded by ISGs can inhibit viral entry, block viral replication steps, degrade viral nucleic acids or limit protein synthesis in infected cells. Interferons also up-regulate major histocompatibility complex molecules, improving recognition of infected or transformed cells by T lymphocytes and natural killer cells.

Physiological roles and clinical relevance

Interferons are central to early control of viral infections and contribute to antitumor immunity. Their systemic release during infection produces common symptoms such as fever and muscle aches. Recombinant interferons have been developed as medicines: examples include interferon-alpha preparations used historically in some chronic viral infections and cancers, interferon-beta used in certain autoimmune neurologic conditions, and investigational uses for other diseases. Therapeutic use is limited by side effects (flu-like symptoms, fatigue, and sometimes more serious toxicities) and by the ability of many viruses to evolve countermeasures that block interferon signaling.

History and research directions

Interferons were first described in the 1950s as factors that protected cells from viral infection, and later work identified their molecular nature, receptors and signaling pathways. Modern research explores ways to enhance beneficial interferon responses while minimizing harmful inflammation, to exploit interferons in cancer immunotherapy and to understand how chronic interferon signaling can contribute to autoimmune disease. Advances in recombinant protein production and biologic engineering have allowed modified interferons and delivery approaches to be tested in clinical trials.

Distinctions and notable facts

  • Type I interferons (for example IFN‑alpha and IFN‑beta) are produced widely by many cell types during viral infection.
  • Type II interferon (IFN‑gamma) is primarily produced by activated T cells and natural killer cells and has strong immunomodulatory roles.
  • Type III interferons (IFN‑lambda) act mainly on epithelial surfaces and use a distinct receptor complex.
  • Interferons affect immune cell activity, for example enhancing the cytotoxicity of natural killer cells and the microbicidal capacity of macrophages.
  • Because interferon signaling is a conserved defense, many pathogens have evolved strategies to evade or block IFN responses.

For more detailed biochemical, clinical and therapeutic information see references and specialist reviews; basic introductions and patient-oriented summaries are available from public health resources and textbooks. Further reading on adaptive interactions between interferons and pathogens can be found via authoritative sources (review summaries, clinical guidance, research articles, and educational materials).